Skip to Main Navigation
Skip to Page Content
Share This:

Target Organs and Levels of Evidence for TR-522

Toxicology and Carcinogenesis Studies of Transplacental AZT (CASRN 30516-87-1) in Swiss (CD-1®) Mice (in utero Studies)

Chemical (Study Title)
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
AZT transplacental carcinogenesis study
12/09/2004Chemotherapeutic agent. Special study involving in utero exposure using AZTIn Utero
AZT: 50, 100, 200, OR 300 MG/KG/DAY; 25, 25, 36, OR 46 PER GROUP
Southern Research Institute

Levels of Evidence

Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Lung: ALVEOLAR/BRONCHIOLAR CARCINOMA 5/50 11/50 6/50 11/37 8/32 ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 14/50 20/50 13/50 18/37 18/32
Female Mice: No Evidence